Blog
RSS FeedPosted by Michael Wonder on 03 Apr 2020
COVID-19 and the supply and distribution of generic and biosimilar prescription medicines in Canada
1 April 2020 - The following is a statement from Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA) ...
Posted by Michael Wonder on 24 Feb 2020
Alberta’s switch to biosimilar drugs may pose legal challenges for doctors
24 February 2020 - Prescribing cheaper medications for arthritis, diabetes or Crohn’s disease could be at odds with physicians’ legal requirement ...
Posted by Michael Wonder on 13 Dec 2019
Alberta changes coverage of biologic drugs for people with Crohn's, diabetes, arthritis
12 December 2019 - The provincial government says will free up hundreds of millions of dollars in health funding during the ...
Posted by Michael Wonder on 12 Dec 2019
Canadian study shows substantial savings possible with use of biosimilar filgrastim
12 December 2019 - During this week’s annual meeting of American Society of Hematology, researchers from Canada reported that using biosimilar ...
Posted by Michael Wonder on 12 Dec 2019
Alberta will force patients to switch from biologics to cheaper biosimilar medications
12 December 2019 - Alberta will force 26,000 patients on government-sponsored drug plans to switch from expensive drugs that are known ...
Posted by Michael Wonder on 18 Nov 2019
Biosimilars make progress in the Canadian market, but stakeholders see more work ahead
18 November 2019 - While much attention over the past few weeks has been on the US biosimilars market, with its ...
Posted by Michael Wonder on 10 Sep 2019
Erosion of physician and patient treatment choice continues - Alliance for Safe Biologic Medicines raises concerns for patients as British Columbia expands biologics forced switching policy
10 September 2019 - On 5 September, the Government of British Columbia announced that it would be forcibly switching 1,700 patients ...
Posted by Michael Wonder on 20 Jul 2019
Biosimilar drugs a boon to be applauded as they provide equivalent treatment at – sometimes – half the price
19 July 2019 - The fastest-growing segment of our health-care system is prescription drugs – now constituting the second-highest category ...
Posted by Michael Wonder on 24 Jun 2019
Forcing patients to switch to biosimilars puts them in uncharted waters
23 June 2019 - On May 27, the B.C. government announced a policy that will forcibly switch thousands of patients, ...
Posted by Michael Wonder on 18 Jun 2019
Advisory Council supports biosimilars in call for universal public drug coverage in Canada
17 June 2019 - A Canadian advisory council is recommending the use of biosimilars in a final report that lays ...
Posted by Michael Wonder on 06 Jun 2019
Patients, physicians raise concerns with BC biosimilar non-medical switching policy
6 June 2019 - On 27 May, the Government of British Columbia announced a policy that will forcibly switch thousands ...
Posted by Michael Wonder on 28 May 2019
Canadian Biosimilars Forum applauds B.C. Government's landmark decision to enhance adoption of biosimilars and calls on remaining provinces to follow
27 May 2019 - The Canadian Biosimilars Forum today commends the Government of British Columbia for taking a decisive step ...
Posted by Michael Wonder on 28 May 2019
BC PharmaCare’s Biosimilars Initiative an important step towards improving patient access to safe and effective medicines
27 May 2019 - Biosimilars Initiative implementation could contribute to significant cost savings for the BC health care system. ...
Posted by Michael Wonder on 27 May 2019
B.C. becomes first province to force change to biosimilar drugs
27 May 2019 - The change will save the government nearly $100 million over the next three years. ...
Posted by Michael Wonder on 23 May 2019
Biosimilars no longer reviewed through the CADTH CDR and pCODR processes
23 May 2019 - When CADTH launched a new, streamlined biosimilar review process in February 2018, we committed to evaluating ...